SEQENS has decided to invest €65M to increase its development and production capacities for active ingredients and pharmaceutical intermediates and to accelerate the deployment of breakthrough technologies on its sites.

These projects should make it possible not only to meet the growing demand for the development and production of critical molecules, but also to complete SEQENS’ industrial capabilities, to produce highly active ingredients and to produce intermediates thanks to flow chemistry technology.

New production unit for highly active ingredients inaugurated in August 2020 on the Seqens CDMO Villeneuve-La-Garenne site
New production unit for highly active ingredients inaugurated in August 2020 on the Seqens CDMO Villeneuve-La-Garenne site

To carry out these projects, SEQENS relies on its Seqens’Lab in Porcheville (one of Seqens’ R&D centers) and on four of its active ingredients and GMP or non-GMP intermediates production sites.

The group has set up an organization dedicated to the management of these projects to ensure that they will be carried out on time and in accordance with our commitments and to limit the impact on our current and future projects for our customers.

Based on breakthrough technologies that guarantee a high level of performance, particularly in terms of safety and environment, the new units will enable competitive and sustainable production of these critical molecules on our production facilities.

The Seqens Group is proud to participate in the development of value chains that are essential for the European health security and the health of our fellow citizens. The future of our industry will depend on the ability of our pharmaceutical synthesis companies to innovate and boost productive investments. SEQENS is ready to take up the challenge while relying on innovation, R&D and the skills of our teams on our production sites!

Pierre Luzeau

SEQENS’ President

Questions & Answers about SEQENS’ PROJECTS

DISCOVER OUR NEWS

Learn more